AstraZeneca Profit Margin 2010-2024 | AZN

Current and historical gross margin, operating margin and net profit margin for AstraZeneca (AZN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. AstraZeneca net profit margin as of September 30, 2024 is 12.68%.
AstraZeneca Annual Profit Margins
AstraZeneca Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $209.663B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $755.038B 78.21
Novo Nordisk (NVO) Denmark $479.268B 34.56
Johnson & Johnson (JNJ) United States $373.206B 15.14
AbbVie (ABBV) United States $323.263B 17.02
Merck (MRK) United States $257.112B 17.08
Novartis AG (NVS) Switzerland $216.194B 14.37
Pfizer (PFE) United States $148.532B 10.16
Sanofi (SNY) $123.059B 11.15
Innoviva (INVA) United States $1.189B 9.89